Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of ASP7962 in Healthy Volunteers
NCT02136316Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP7962 in osteoarthritis (OA) (4 arms), sponsored by Astellas Pharma. Primary endpoints: Safety as assessed by adverse events up to 29 days, Safety as assessed by vital signs up to 29 days and 7 more. Started May 2014; status: completed.
02
Drugs
ASP7962
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02136316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02136316.